Crystal Engineering Approaches for Improving Solubility of BCS Class II Drugs: Focus on Cocrystallization

Poor water solubility of active pharmaceutical ingredients (APIs), which directly impacts medication dissolution, absorption, and bioavailability, poses a major obstacle to the development of efficient oral drug delivery systems. One of the most important problems in pharmaceutical research and formulation design is low water solubility, which has been estimated to affect up to 70% of therapeutic candidates in development and nearly 40% of commercialized medications [1,2]. Inadequate solubility frequently results in dissolution rate-limited absorption, which causes pharmacokinetic profile variability and less than ideal therapeutic efficacy [3]. The Biopharmaceutics Classification System (BCS), a scientific framework that classifies medications according to their intestinal permeability and solubility, was created to solve these issues. Class I (high solubility, high permeability), Class II (low solubility, high permeability), Class III (high solubility, low permeability), and Class IV (low solubility, low permeability) are the four groups into which the system divides pharmaceuticals [3]. Approximately 30% of commercialized medications and up to 70% of compounds in research pipelines are BCS Class II pharmaceuticals, which make up a significant part of poorly soluble compounds [3]. Dissolution is the rate-limiting step for absorption since these medications have sufficient membrane permeability but low water solubility [1,3]. Solubility-related problems have been made worse by the growing number of lipophilic and structurally complicated compounds produced by contemporary drug development methods like high-throughput screening [3]. As a result, improving the solubility and rate of dissolution of BCS Class II medications has emerged as a key objective in the development of pharmaceutical formulations. Particle size reduction (micronization, nanonization), salt production, solid dispersions, the use of surfactants, and complexation procedures are some of the traditional methods used to increase solubility [1,4]. These techniques can improve solubility, but they frequently have serious drawbacks such poor physical stability, recrystallization, hygroscopicity, and difficulties scaling up, which could jeopardize product performance and manufacturability [1,4].

Table 1: Classification of BCS System

Crystal engineering has become a viable and sensible way to get around these restrictions in recent years. Without changing the chemical structure of the drug molecule, crystal engineering entails designing and modifying solid-state structures by manipulating intermolecular interactions including hydrogen bonding, van der Waals forces, and π–π interactions [5]. New solid forms with enhanced physicochemical characteristics, such as solubility, dissolution rate, stability, and mechanical behavior, can be created using this method. Cocrystallization has drawn a lot of interest among other crystal engineering techniques as a successful method for improving the solubility of poorly water-soluble medications, especially those that fall under BCS Class II [2,5]. Pharmaceutical cocrystals provide the benefit of customizing drug characteristics while preserving pharmacological activity. They are made up of API and an appropriate coformer in a certain stoichiometric ratio. Thus, crystal engineering, especially through cocrystallization, represents a modern and versatile strategy to address solubility challenges and improve the performance of BCS Class II drugs in pharmaceutical development.

Figure 1: BCS Classification Diagram

1.Fundamentals of Crystal Engineering

The methodical process of designing and creating solid-state structures by comprehending and modifying intermolecular interactions is known as "crystal engineering." "The understanding of intermolecular interactions in the context of crystal packing and the utilization of such understanding in the design of new solids with desired physical and chemical properties" is Gautam R. Desiraju's formal definition [1]. In order to customize physicochemical characteristics including solubility, stability, and mechanical behavior without changing the molecular structure of the active pharmaceutical ingredient (API), this subject combines concepts from chemistry, materials science, and pharmaceutics [2].

Principles of Crystal Engineering

Controlling the non-covalent intermolecular interactions that determine how molecules are arranged in the crystal lattice is the basic idea behind crystal engineering. Crystal habit, polymorphism, and ultimately the drug's physicochemical performance are determined by these interactions. Predicting and creating crystal structures depend heavily on the idea of supramolecular synthons, which are recurrent structural units created by certain intermolecular interactions [1, 3]. Choosing molecules (or coformers) with complementary functional groups that can create stable and predictable interactions is a key component in rational crystal design.

Intermolecular Interactions

Because they control molecule organization and lattice stability, intermolecular forces are essential to crystal engineering. The most significant exchanges consist of:
Bonding of Hydrogen . In crystal engineering, hydrogen bonding is the most prevalent and directed interaction. It takes place between an acceptor (like O, N) and a hydrogen donor (like –OH, –NH). By altering lattice energy, hydrogen bonds have a major impact on crystal stability, solubility, and dissolution rate [2,4]. Pharmaceutical cocrystal design frequently makes use of strong and consistent hydrogen bonding interactions.

π–π Stacking Interactions

The stability of crystal structures, particularly in aromatic medicinal compounds, is facilitated by π–π stacking interactions, which result from the stacking of aromatic rings. Dissolution behavior is impacted by these interactions, which also alter electrical characteristics and crystal packing density [2].

Van der Waals Forces 

These interactions are non-specific, weak, and supportive to crystal packing. Despite being poor on their own, their combined action supports molecular organization and overall lattice stability [3].

Role of Supramolecular Chemistry

Because it deals with how molecules are arranged through non-covalent interactions, supramolecular chemistry—often referred to as "chemistry beyond the molecule"—is essential to crystal engineering. Jean-Marie Lehn, who focused on molecular recognition and self-assembly processes, greatly advanced the idea [5].     Supramolecular chemistry makes it possible for multicomponent crystals like cocrystals to form in pharmaceutical systems, where APIs and coformers interact via predictable bonding patterns. This method enables the logical design of solid forms with optimum dissolving profiles, increased solubility, and improved stability [2,5].

Crystal Packing and Its Influence on Physicochemical Properties

     The three-dimensional arrangement of molecules inside a crystal lattice is referred to as crystal packing. Packing efficiency is determined by the kind and strength of intermolecular interactions, which directly affects important physicochemical features like:

• Solubility: Because of their lower lattice energy, loosely packed structures with weaker intermolecular interactions typically show higher solubility [4].

• Dissolution rate: Faster drug release and solvent penetration are made possible by lower packing density.

• Thermal stability: Higher melting points and improved stability result from robust and well-organized packing.

 • Mechanical properties: Compressibility, flowability, and tabletability—all essential for pharmaceutical processing—are impacted by crystal packing [2, 4].      

These characteristics can be optimized without changing the pharmacological action of the medication by modifying crystal packing using crystal engineering techniques like cocrystallization. Therefore, creating superior pharmaceutical solid forms requires an understanding of and control over crystal packing and intermolecular interactions.

Figure 2: Crystal Engineering Concept

2.Solid-State Modification Techniques

Several solid-state modification techniques have been developed to increase the solubility of weakly water-soluble medications, especially BCS Class II compounds. These methods seek to enhance the drug's bioavailability and dissolving behavior without changing its pharmacological action [1].

Polymorphism

The ability of a material to exist in multiple crystalline forms with the same chemical makeup but distinct molecular configurations in the crystal lattice is known as polymorphism. Physicochemical characteristics including solubility, dissolution rate, and stability are greatly impacted by this phenomena [2].  Lattice energies vary among polymorphs; in general, metastable polymorphs are more soluble and dissolve more quickly than their stable counterparts because of weaker intermolecular interactions [2,3]. However, with time, metastable forms may undergo phase transformation to more stable forms, which could result in decreased solubility and possible medication performance variability [3]. Ritonavir is a well-known example of a drug whose unexpected polymorphic change resulted in decreased bioavailability and product recall [3].

Salt Formation

One of the most popular methods for increasing the solubility of ionizable medications is salt production. In order to create a crystalline salt that improves water solubility, dissolving rate, and occasionally stability, an API must react with an appropriate counterion [1, 4].
The pKa difference between the medication and the counterion is a major factor in the efficacy of salt formation; a difference of more than two to three units is usually necessary for successful salt formation [4]. This strategy has a number of drawbacks despite its benefits, such as:
• Only applicable to medications that are ionizable

• The possibility of instability and hygroscopicity

• A potential change in pharmacokinetics

• A small range of counterions that are pharmaceutically acceptable [4,5]

Solid Dispersions

By dispersing a poorly soluble medication in an inert hydrophilic carrier matrix, solid dispersions improve the drug's solubility and dissolution. The main components of the mechanism are:

• Particle size reduction

• Enhanced wettability

• Transformation of a crystalline medication into an amorphous form with a greater free energy [1,6].

Nanocrystals

According to the Noyes-Whitney equation [7], nanocrystal technology increases surface area and improves dissolving velocity by lowering drug particle size to the nanometer range (usually <1000 nm).

The following factors are responsible for nanocrystals' improved performance:

• A higher ratio of surface area to volume

• Enhanced solubility at saturation

• Improved biological membrane adhesion [7]

Despite these benefits, physical instability, aggregation, and complicated production procedures may limit the practical use of nanocrystals [7, 8].

Cocrystals (Transition Section)

Cocrystallization has become one of the most effective and adaptable solid-state modification methods for increasing the solubility of medications that are poorly soluble in water. Pharmaceutical cocrystals are crystalline materials that are kept together by non-covalent interactions like hydrogen bonding and consist of an API and a neutral coformer in a specific stoichiometric ratio [1,9]. Cocrystals provide a number of benefits over traditional techniques, including:

• Unlike salts, it applies to both ionizable and non-ionizable medications.

• Compared to amorphous solid dispersions, they offer superior physical stability.

• Make it possible to adjust physicochemical characteristics without changing the chemical structure.
• Phase transformation danger is lower than that of polymorphs [9]. 

Table 2: Comparison of Solid-State Modification Techniques

3.Pharmaceutical Cocrystals

A sophisticated crystal engineering technique to enhance the physicochemical characteristics of active pharmaceutical ingredients (APIs), specifically solubility and dissolution rate, is pharmaceutical cocrystals. Because of their adaptability and regulatory approval, they are becoming more widely acknowledged as a competitive substitute for conventional solid-state modification methods.

Definition and Regulatory Perspective

Pharmaceutical cocrystals are multicomponent crystalline structures that are held together by non-covalent interactions and consist of an API and one or more neutral molecular coformers in a specific stoichiometric ratio [10]. In contrast to salts, cocrystals rely on intermolecular forces including hydrogen bonding and π–π interactions instead of proton transfer.
Regarding pharmaceutical cocrystals, regulatory bodies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have issued explicit guidelines. As long as the API doesn't change, the FDA considers cocrystals similarly to polymorphs and categorizes them as drug product intermediates rather than novel active ingredients [11]. Additionally, the EMA acknowledges cocrystals as unique solid structures and highlights how they might change physicochemical characteristics without changing pharmacological action [12]. Proton transfer is a crucial difference between cocrystals and salts. While cocrystals are frequently created when ΔpKa is less than this threshold, resulting in neutral species interacting via non-covalent forces, salt production usually happens when ΔpKa > 3 between the acid and base, leading to ionization [13]. For regulatory classification and formulation strategy, this distinction is essential.

Components of Cocrystals

Coformer cocrystals and active pharmaceutical ingredients (API) are made up of two primary parts:

• The therapeutic effect is provided by the API

• The coformer, a compound that improves physicochemical characteristics and is approved

for use in pharmaceuticals- To guarantee safety and regulatory compliance, coformers are usually chosen from compounds classified as Generally Recognized as Safe (GRAS) chemicals [14]. Organic acids (like fumaric acid and citric acid), amides (like nicotinamide), and sugars

are common coformers.

Selection Standards for Coformers

For cocrystal formation to be successful, coformers must be carefully chosen. Crucial

requirements consist of:

• The existence of complementary functional groups (such as -COOH, -OH, and -NH?) that can form predictable relationships

• The capacity to create stable supramolecular synthons

• Appropriate physicochemical compatibility (melting point, solubility, etc.) with the API [14,15]

Table 3: Common Coformers Used in Cocrystals

Types of Interactions in Cocrystals

For pharmaceutical cocrystals to develop and remain stable, intermolecular interactions are

essential. The most significant exchanges consist of:

Bonding of Hydrogen

Because of its strength, directionality, and predictability, hydrogen bonding is the main driver behind the development of cocrystals. Strong supramolecular synthons are formed when it usually takes place between hydrogen donors (–OH, –NH) and acceptors (O, N) [10,16]. Solubility, dissolution behavior, and crystal packing are all strongly influenced by hydrogen bonding.

π–π Interactions

π–π stacking interactions occur between aromatic rings and contribute to crystal stabilization  and packing efficiency. These interactions are particularly relevant for APIs containing aromatic structures and can influence electronic distribution and dissolution characteristics [16].

Halogen Bonding

Halogen bonding is a relatively newer interaction in pharmaceutical crystal engineering, involving halogen atoms (e.g., Cl, Br, I) acting as electrophilic species interacting with nucleophilic sites (e.g., O, N). These interactions are highly directional and comparable in strength to hydrogen bonds, making them useful in designing novel cocrystal architectures [17].

4.Design Strategies for Cocrystal Formation

Rational design techniques that allow for the prediction and management of intermolecular interactions between the API and coformer are essential for the effective production of pharmaceutical cocrystals. These techniques increase the effectiveness of cocrystal discovery and development by combining concepts from thermodynamics, computer modeling, and supramolecular chemistry.

Synthon Approach (Supramolecular Synthons)

Gautam R. Desiraju invented the synthon method, which is one of the most popular techniques in crystal engineering. A recurrent structural unit within a crystal created by particular and predictable intermolecular interactions, most frequently hydrogen bonding, is known as a supramolecular synthon [18].

In general, synthons fall into:

• Homosynthons: created when two functional groups are identical (carboxylic acid–carboxylic

acid dimers, for example).

• Heterosynthons: created by interactions between various functional groups, such as carboxylic acid–amide

By discovering complementary functional groups that may establish stable contacts, the synthon method enables the sensible selection of coformers. Because it offers a predictive framework for crystal structure development, this approach has been effectively used to create cocrystals with increased solubility [18,19].

The Significance of the pKa Rule

An essential criterion for determining whether a system will form a salt or a cocrystal is the pKa rule. It is predicated on the variation in pKa values (ΔpKa) between the proton acceptor (base) and donor (acid):

• ΔpKa > 3 → Salt production (presumably due to proton transfer) • ΔpKa < 0 → Favored

cocrystal formation (no proton transfer)

• ΔpKa in the range of 0–3 → Salt–cocrystal continuum (unknown result)

For choosing coformers and forecasting solid-state results, this rule offers a helpful initial screening tool [19]. However, there are outliers because of the impact of solvent effects, particular intermolecular interactions, and crystal packing, suggesting that experimental confirmation is still crucial [20].

Methods of Computational Prediction

Predicting cocrystal formation and stability has become much easier thanks to developments in computational chemistry. These techniques increase the success rate of cocrystal screening while lowering the experimental burden. Important computational methods consist of:
• Calculating interaction energy and molecular docking to assess API-coformer compatibility
• Density Functional Theory (DFT) for calculating hydrogen bonding strength and binding energies

• To find potential stable crystal forms, use crystal structure prediction (CSP).
• Hansen solubility parameter computations to evaluate API and coformer miscibility
These methods allow coformers to be virtually screened, saving time and money while revealing molecular-level interactions [21, 22]. Despite their benefits, computational approaches need experimental validation and may not be able to predict complicated crystal packing with sufficient accuracy.

High-Throughput Screening Techniques

High-throughput screening (HTS), which enables quick assessment of several API–coformer pairings under various circumstances, has emerged as a crucial technique in cocrystal discovery. HTS methods include:

• Automated techniques for crystallization and solvent evaporation

• Experiments with parallel grinding (neat and liquid-assisted grinding)

• Using multi-well plates for micro-scale crystallization

These techniques allow for the systematic tuning of crystallization settings and greatly speed up the discovery of appropriate cocrystal candidates [22]. For quick characterisation, HTS is frequently used in conjunction with analytical methods like PXRD and DSC.
A more effective and logical approach to cocrystal development has resulted from the integration of HTS with computational tools and synthon-based design, making it ideal for industrial applications.

Table 4: Cocrystal Design Strategies

5.Methods of Cocrystal Preparation

Pharmaceutical cocrystals are created using a range of methods that allow regulated intermolecular interactions to form multicomponent crystalline structures. The physicochemical parameters of the coformer and API, the need for scalability, and the required crystal qualities all influence the method selection.

Solvent-Based Techniques

Crystallization of Solutions

One of the most widely used techniques for cocrystal production is solution crystallization. This method causes cocrystal nucleation and development by dissolving the API and coformer in an appropriate solvent or solvent mixture, then allowing for controlled supersaturation or slow evaporation [23]. This technique is very helpful for producing high-quality single crystals appropriate for structural study since it permits exact control over crystal size and morphology. Nevertheless, drawbacks include difficulties choosing a solvent, the possibility of solvate production, and occasionally low yield [23, 24].

Crystallization Cooling

In order to cause supersaturation and crystallization, cooling crystallization entails dissolving the API and coformer at a high temperature and then lowering the temperature [24]. This approach is appropriate for industrial applications because it provides benefits including improved control over nucleation kinetics and scalability. To prevent undesirable polymorphs or phase separation, cooling rates and solvent systems must be carefully optimized [24].

Solid-State Methods

Grinding (Liquid-Assisted and Neat)

A popular solid-state method that uses mechanical energy input to promote cocrystal formation is grinding.

• Neat Grinding (NG): Without the use of a solvent, API and coformer are crushed together.
• Liquid-Assisted Grinding (LAG): To improve molecular mobility, a certain amount of solvent is applied.

By boosting surface contact and promoting intermolecular interactions, grinding encourages the production of cocrystals [25]. Because LAG improves component diffusion and interaction, it is frequently more effective than plain grinding. Solvent reduction, ease of use, and quick screening are among the benefits; scale-up challenges and a lack of control over crystal habit and size are among the drawbacks [25,26].

Advanced Techniques

Supercritical Fluid Method

Supercritical fluid (SCF) technology, particularly using supercritical CO?, has emerged as a green and efficient method for cocrystal preparation. In this technique, the API and coformer are dissolved or suspended in a supercritical fluid, followed by rapid expansion or anti-solvent precipitation to form cocrystals [27].

Advantages include:

• Minimal solvent residue
• Environmentally friendly processing
• Ability to produce uniform particle sizes

However, high operational cost and requirement for specialized equipment limit its widespread use [27].

Spray Drying

Spray drying involves atomizing a solution containing the API and coformer into a hot drying chamber, resulting in rapid solvent evaporation and formation of cocrystals [28]. This method enables continuous processing, scalability, and control over particle size distribution, making it attractive for industrial applications. However, challenges include thermal degradation of heat-sensitive drugs and potential formation of amorphous phases [28].

Hot Melt Extrusion (HME)

Hot melt extrusion is a solvent-free technique in which the API and coformer are mixed and subjected to heat and mechanical shear to induce cocrystal formation [29].

HME offers several advantages:

• Continuous and scalable manufacturing
• No solvent-related issues
• Improved homogeneity and reproducibility

However, its applicability is limited to thermally stable compounds, and optimization of processing parameters such as temperature and screw speed is critical [29]. Overall, the selection of an appropriate cocrystal preparation method depends on balancing efficiency, scalability, environmental considerations, and physicochemical stability, with advanced techniques gaining increasing importance in industrial pharmaceutical development.

Table 5: Methods of Cocrystal Preparation

6.Characterization of Cocrystals

 The successful development of pharmaceutical cocrystals requires comprehensive characterization to confirm their formation, structural arrangement, and physicochemical properties. A combination of spectroscopic, thermal, crystallographic, and morphological techniques is typically employed to establish the identity and performance of cocrystals.

FTIR Spectroscopy (Intermolecular Interactions)

Fourier Transform Infrared (FTIR) spectroscopy is widely used to identify intermolecular interactions, particularly hydrogen bonding, in cocrystals. Formation of cocrystals often results in shifts in characteristic vibrational frequencies (e.g., –OH, –NH, C=O stretching), indicating interaction between the API and coformer [30]. For example, hydrogen bond formation may lead to broadening or shifting of peaks toward lower wavenumbers, confirming the establishment of supramolecular synthons. FTIR thus serves as a rapid and reliable technique for preliminary confirmation of cocrystal formation [30,31].

DSC (Differential Scanning Calorimetry) – Thermal Behavior

Differential Scanning Calorimetry (DSC) is a critical thermal analysis technique used to evaluate melting behavior, phase transitions, and thermal stability of cocrystals. Cocrystals typically exhibit a single, sharp endothermic peak corresponding to a melting point distinct from those of the pure API and coformer, indicating the formation of a new crystalline phase [31]. DSC can also detect polymorphic transitions, eutectic formation, and amorphous content, making it essential for assessing purity and stability [32].

PXRD (Powder X-ray Diffraction) – Crystallinity

Powder X-ray Diffraction (PXRD) is the most definitive technique for confirming cocrystal formation. Each crystalline material produces a unique diffraction pattern, and the appearance of new characteristic peaks distinct from the parent components confirms the formation of a new solid phase [33]. PXRD is also used to assess crystallinity, phase purity, and polymorphic transformations, making it indispensable in solid-state characterization [33,34].

Single Crystal XRD

Single crystal X-ray diffraction is considered the gold standard for structural characterization of cocrystals. It provides detailed information on:

• Atomic arrangement and molecular conformation
• Intermolecular interactions (e.g., hydrogen bonds, π–π stacking)
• Stoichiometry and crystal lattice parameters

This technique enables direct visualization of supramolecular synthons and confirms the exact nature of cocrystal formation [34]. However, its application is limited by the requirement for high-quality single crystals.

SEM (Scanning Electron Microscopy)

Scanning Electron Microscopy (SEM) is used to examine the surface morphology and particle size of cocrystals. It provides insights into:

• Crystal habit (shape and structure)
• Surface texture
• Particle aggregation

Changes in morphology compared to pure components indicate successful cocrystal formation and can influence flowability, compressibility, and dissolution behavior [35].

Solubility and Dissolution Studies

Solubility and dissolution studies are critical for evaluating the performance enhancement achieved through cocrystallization.

• Saturation solubility studies determine equilibrium solubility in various media
• In vitro dissolution studies assess the rate and extent of drug release

Cocrystals often demonstrate enhanced solubility and faster dissolution rates due to reduced lattice energy and improved wettability [36]. These studies are typically conducted using USP dissolution apparatus under standardized conditions to ensure reproducibility and comparability. Improved dissolution profiles directly correlate with enhanced oral bioavailability, making these studies essential for evaluating the pharmaceutical relevance of cocrystals [36].

Table 6: Characterization Techniques for Cocrystals

7. Mechanisms of Solubility Enhancement

The enhancement of solubility and dissolution rate in pharmaceutical cocrystals is primarily governed by modifications in solid-state properties without altering the chemical structure of the active pharmaceutical ingredient (API). These improvements arise from changes in lattice energy, surface characteristics, crystallinity, and the influence of coformers on dissolution behavior.

Improved (Reduced) Lattice Energy

One of the key mechanisms behind solubility enhancement in cocrystals is the reduction in lattice energy compared to the pure crystalline API. In a crystal lattice, molecules are held together by intermolecular forces; stronger interactions result in higher lattice energy and lower solubility. Cocrystal formation introduces heteromolecular interactions (API–coformer) that are often weaker or less tightly packed than homomolecular interactions in the pure drug crystal. This leads to a less stable crystal lattice, which requires less energy to break during dissolution, thereby enhancing solubility [37]. Studies have demonstrated that modifying lattice energy through cocrystallization can significantly improve dissolution rates of poorly soluble drugs, especially those belonging to BCS Class II [38].

Enhanced Wettability

Wettability refers to the ability of a solid surface to interact with a liquid, which plays a crucial role in dissolution. Poorly soluble drugs often exhibit hydrophobic surfaces, limiting their interaction with aqueous media. In cocrystals, the incorporation of hydrophilic coformers (e.g., organic acids, amides) enhances surface polarity and hydrogen bonding with water molecules, thereby improving wettability [38]. Improved wettability facilitates faster penetration of dissolution media, leading to enhanced drug release. Contact angle measurements have shown that cocrystals typically exhibit lower contact angles compared to pure APIs, indicating improved wettability and dissolution performance [39].

Reduced Crystallinity

Cocrystallization can lead to a reduction in effective crystallinity or crystal packing efficiency, even though cocrystals remain crystalline in nature. The introduction of a coformer disrupts the original crystal lattice, resulting in:

• Reduced packing efficiency
• Increased free volume
• Lower crystal density

These factors contribute to enhanced molecular mobility and easier solvent access, which promote faster dissolution [37,40]. Although not amorphous, cocrystals may exhibit dissolution behavior similar to partially disordered systems due to their modified lattice structure.

Role of Coformer in Dissolution

The coformer plays a critical role in determining the dissolution behavior of cocrystals. Its contribution includes:

• Improving solubility by forming soluble complexes with the API
• Acting as a carrier that enhances drug release
• Modifying microenvironmental pH, especially when acidic or basic coformers are used
• Enhancing drug–solvent interactions through hydrogen bonding

In some cases, coformers dissolve rapidly, creating a localized supersaturated environment that promotes API dissolution [39]. Additionally, coformers can inhibit recrystallization of the API in solution, thereby maintaining supersaturation and improving bioavailability [40]. Overall, the synergistic interaction between API and coformer is essential for achieving optimal solubility enhancement in pharmaceutical cocrystals.

Table 7: Mechanisms of Solubility Enhancement

8. Applications in BCS Class II Drugs

Cocrystallization has been widely applied to BCS Class II drugs to address solubility-limited bioavailability. Numerous case studies demonstrate significant improvements in solubility, dissolution rate, and in some cases, oral bioavailability through rational cocrystal design.

Case Studies

Carbamazepine - Carbamazepine is a well-known BCS Class II drug exhibiting poor aqueous solubility (~0.1–0.2 mg/mL). Cocrystals of carbamazepine with coformers such as nicotinamide and saccharin have shown 2–5 fold enhancement in solubility and significantly improved dissolution rates compared to the pure drug [41]. These cocrystals also demonstrate improved physical stability compared to amorphous forms.

Ibuprofen - Ibuprofen is another BCS Class II drug with low solubility (~21 mg/L). Cocrystals of ibuprofen with coformers like nicotinamide and isonicotinamide have been reported to exhibit enhanced dissolution rates and improved wettability, leading to faster drug release [42]. Some studies indicate up to 3-fold improvement in dissolution efficiency compared to the pure drug.

Ketoconazole - Ketoconazole is a poorly water-soluble antifungal agent with pH-dependent solubility. Cocrystal formation with dicarboxylic acids (e.g., succinic acid) has shown significant improvement in dissolution rate and solubility under physiological conditions [43]. These systems help overcome variability in absorption associated with gastric pH.

Ferulic Acid - Ferulic acid is a natural antioxidant with poor aqueous solubility, limiting its pharmaceutical application. Cocrystal formation with coformers such as nicotinamide has been reported to result in enhanced solubility and improved dissolution profiles, primarily due to hydrogen bonding and reduced lattice energy [44]. This makes ferulic acid cocrystals a promising approach for improving its oral bioavailability and therapeutic consistency, aligning directly with your research work.

Comparative Solubility Data

Comparative studies clearly demonstrate the advantages of cocrystals over pure drugs and other solid forms:

• Carbamazepine cocrystals: 2–5× increase in solubility
• Ibuprofen cocrystals: ~2–3× enhancement in dissolution rate
• Ketoconazole cocrystals: significant improvement in dissolution across pH range
• Ferulic acid cocrystals: notable increase in saturation solubility and dissolution rate

These improvements are attributed to modified crystal packing, reduced lattice energy, and enhanced wettability, which collectively improve drug performance [41–44].

Improvement in Bioavailability

Enhanced solubility and dissolution rates achieved through cocrystallization often translate into improved oral bioavailability.

• Faster dissolution leads to increased drug concentration at the absorption site
• Improved wettability enhances drug–membrane interaction
• Maintenance of supersaturation can result in higher systemic exposure

In several studies, cocrystals have demonstrated improved pharmacokinetic parameters such as Cmax and AUC, indicating enhanced bioavailability compared to the pure drug [45]. Thus, cocrystallization serves as an effective strategy for overcoming solubility-limited absorption in BCS Class II drugs, making it highly relevant for modern pharmaceutical development.

Table 8: Case Studies of BCS Class II Drugs